D F Easton

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. pmc Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13
    D F Easton
    CRC Genetic Epidemiology Unit, Institute of Public Health, Cambridge, United Kingdom
    Am J Hum Genet 61:120-8. 1997
  2. pmc Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies
    A Antoniou
    Cancer Research U K Genetic Epidemiology Unit, Department of Public Health, University of Cambridge, Cambridge, United Kingdom
    Am J Hum Genet 72:1117-30. 2003
  3. ncbi request reprint Risk models for familial ovarian and breast cancer
    A C Antoniou
    CRC Genetic Epidemiology Unit, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom
    Genet Epidemiol 18:173-90. 2000
  4. pmc A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes
    A C Antoniou
    CRC Genetic Epidemiology Unit, Institute of Public Health, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge CB1 8RN, UK
    Br J Cancer 86:76-83. 2002
  5. ncbi request reprint Family history and the risk of breast cancer: a systematic review and meta-analysis
    P D Pharoah
    Institute of Public Health, Cambridge, UK
    Int J Cancer 71:800-9. 1997
  6. pmc The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes
    S A Gayther
    Department of Oncology, Cancer Research Campaign, Strangeways Research Laboratory, Cambridge, United Kingdom
    Am J Hum Genet 65:1021-9. 1999
  7. ncbi request reprint Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)
    M O Leach
    MARIBS Study Office, Section of Magnetic Resonance, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Lancet 365:1769-78. 2005
  8. pmc Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies
    A C Antoniou
    J Med Genet 42:602-3. 2005
  9. pmc The BOADICEA model of genetic susceptibility to breast and ovarian cancer
    A C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Department of Public Health and Primary Care, Worts Causeway, Cambridge CB1 8RN, UK
    Br J Cancer 91:1580-90. 2004
  10. pmc Single-nucleotide polymorphisms in the RB1 gene and association with breast cancer in the British population
    F Lesueur
    Department of Oncology, University of Cambridge, Strangeways Research Laboratories, UK
    Br J Cancer 94:1921-6. 2006

Detail Information

Publications34

  1. pmc Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13
    D F Easton
    CRC Genetic Epidemiology Unit, Institute of Public Health, Cambridge, United Kingdom
    Am J Hum Genet 61:120-8. 1997
    ..89, based on five possible carriers) were also observed. One case of ocular melanoma, as well as a second eye cancer of unspecified histology, occurred in obligate gene carriers...
  2. pmc Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies
    A Antoniou
    Cancer Research U K Genetic Epidemiology Unit, Department of Public Health, University of Cambridge, Cambridge, United Kingdom
    Am J Hum Genet 72:1117-30. 2003
    ..The variation in risk by age at diagnosis of index case is consistent with the effects of other genes modifying cancer risk in carriers...
  3. ncbi request reprint Risk models for familial ovarian and breast cancer
    A C Antoniou
    CRC Genetic Epidemiology Unit, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom
    Genet Epidemiol 18:173-90. 2000
    ..The high penetrance estimate for ovarian cancer, compared with other studies, suggests that modifying genetic or environmental factors may be important determinants of risk...
  4. pmc A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes
    A C Antoniou
    CRC Genetic Epidemiology Unit, Institute of Public Health, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge CB1 8RN, UK
    Br J Cancer 86:76-83. 2002
    ..The modifying effect may explain the previously reported differences between population based estimates for BRCA1/2 penetrance and estimates based on high-risk families...
  5. ncbi request reprint Family history and the risk of breast cancer: a systematic review and meta-analysis
    P D Pharoah
    Institute of Public Health, Cambridge, UK
    Int J Cancer 71:800-9. 1997
    ..8 (CI = 1.6, 2.0); mother and sister, RR = 3.6 (CI = 2.5, 5.0); and a second-degree relative, RR = 1.5 (CI = 1.4, 1.6). Risks were increased in subjects under age 50 and when the relative had been diagnosed before age 50...
  6. pmc The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes
    S A Gayther
    Department of Oncology, Cancer Research Campaign, Strangeways Research Laboratory, Cambridge, United Kingdom
    Am J Hum Genet 65:1021-9. 1999
    ..We discuss the implications for genetic testing and clinical management of familial ovarian cancer arising from the data presented in these studies...
  7. ncbi request reprint Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)
    M O Leach
    MARIBS Study Office, Section of Magnetic Resonance, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Lancet 365:1769-78. 2005
    ..Our aim was, therefore, to compare contrast enhanced magnetic resonance imaging (CE MRI) with mammography for screening...
  8. pmc Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies
    A C Antoniou
    J Med Genet 42:602-3. 2005
    ..These estimates appear to be consistent with the observed prevalence of the mutations in the Ashkenazi Jewish population...
  9. pmc The BOADICEA model of genetic susceptibility to breast and ovarian cancer
    A C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Department of Public Health and Primary Care, Worts Causeway, Cambridge CB1 8RN, UK
    Br J Cancer 91:1580-90. 2004
    ..We conclude that this model provides a rational basis for risk assessment in individuals with a FH of breast or ovarian cancer...
  10. pmc Single-nucleotide polymorphisms in the RB1 gene and association with breast cancer in the British population
    F Lesueur
    Department of Oncology, University of Cambridge, Strangeways Research Laboratories, UK
    Br J Cancer 94:1921-6. 2006
    ..Replication studies are needed to confirm the associations with breast cancer...
  11. pmc Interactions between genes involved in the antioxidant defence system and breast cancer risk
    M Z Oestergaard
    Department of Public Health and Primary Care, Strangeways Research Laboratories, Cambridge CB1 8RN, UK
    Br J Cancer 95:525-31. 2006
    ..12) nor a fifth round with more balanced proportion of missing values between cases and controls (P=0.17) was significant...
  12. ncbi request reprint Polygenic inherited predisposition to breast cancer
    B A J Ponder
    Department of Oncology and Public Health and Cancer Research UK Genetic Epidemiology Unit, Strangeways Research Laboratories, University of Cambridge, UK
    Cold Spring Harb Symp Quant Biol 70:35-41. 2005
    ..A key unanswered question is the "genetic architecture" of predisposition-that is, strong or weak alleles, common or rare. We describe a genome-wide scan designed to provide a first-pass answer to this question...
  13. ncbi request reprint Models of genetic susceptibility to breast cancer
    A C Antoniou
    Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK
    Oncogene 25:5898-905. 2006
    ..Such a model of susceptibility has implications for both risk prediction and for future gene identification studies...
  14. pmc HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer
    P R Benusiglio
    Strangeways Research Laboratory, Cancer Research UK Department of Oncology, University of Cambridge, UK, and Department of Internal Medecine, Hopital Cantonal Universitaire de Geneve, Switzerland
    Br J Cancer 95:1689-95. 2006
    ..We are therefore likely to have tagged any common variants present in our population. In summary, we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women...
  15. pmc The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions
    A C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
    Br J Cancer 98:1457-66. 2008
    ..BOADICEA can be used to predict carrier probabilities and cancer risks to individuals with any family history, and has been implemented in a user-friendly Web-based program (http://www.srl.cam.ac.uk/genepi/boadicea/boadicea_home.html)...
  16. doi request reprint Common variants in mismatch repair genes and risk of colorectal cancer
    T Koessler
    Cancer Research UK Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Worts Causeway, Cambridge, UK
    Gut 57:1097-101. 2008
    ..To assess the putative associations between common variants in MMR genes and CRC, we performed a genetic case-control study using a single-nucleotide polymorphism (SNP) tagging approach...
  17. ncbi request reprint A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome
    R Wooster
    Section of Molecular Carcinogenesis, Institute of Cancer Research, Belmont, Sutton, Surrey, UK
    Nat Genet 2:132-4. 1992
    ..This is the first report of a germline mutation in a member of the steroid/thyroid hormone receptor superfamily associated with the development of cancer...
  18. doi request reprint Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics
    A C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK
    J Med Genet 45:425-31. 2008
    ..Several algorithms that predict the likelihood of carrying a BRCA1 or a BRCA2 mutation are currently used in clinical practice to identify such individuals...
  19. ncbi request reprint Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testing
    B Kuschel
    CRC Human Cancer Genetics Research Group, Department of Oncology, Strangeways Research Laboratories, Cambridge, England
    Genes Chromosomes Cancer 31:96-8. 2001
    ..This may have major implications for the sensitivity of all polymerase chain reaction-based mutation-detection methods in clinical genetic testing laboratories...
  20. pmc CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers
    L Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    Br J Cancer 85:36-40. 2001
    ..We conclude that, in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance, it is likely to be weak...
  21. ncbi request reprint CYP17 promoter polymorphism and breast cancer in Australian women under age forty years
    A B Spurdle
    Cancer Unit, Joint Experimental Oncology Programme, The Queensland Institute of Medical Research, and The University of Queensland, Brisbane, Australia
    J Natl Cancer Inst 92:1674-81. 2000
    ..Because steroid hormone exposure is known to influence breast cancer risk, we conducted a population-based, case-control-family study to assess the relationship between the CYP17 promoter polymorphism and early-onset breast cancer...
  22. ncbi request reprint Polymorphisms in CYP1A1 and smoking: no association with breast cancer risk
    V M Basham
    CRC Human Cancer Genetics Group, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK
    Carcinogenesis 22:1797-800. 2001
    ..9 (0.7-1.1), Val/Val OR = 2.3 (0.4-12), and Val carrier OR = 1.0 (0.9-1.1)]...
  23. pmc HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease
    J C Meitz
    Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 87:905-8. 2002
    ..50, 95% CI 0.79-2.85) or to patients diagnosed >55 years (OR=1.27, 95% CI 0.59-2.74). We conclude that any association between the Thr541 variant and prostate cancer is likely to be weak...
  24. ncbi request reprint Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer
    Z Kote-Jarai
    Section of Cancer Genetics, The Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    Prostate Cancer Prostatic Dis 5:189-92. 2002
    ..67; 95% CI: 0.97-2.87). The result of this study suggests that the GPX1 genotype is unlikely to be associated with the risk of developing prostate cancer...
  25. ncbi request reprint The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS)
    M O Leach
    Section of Magnetic Resonance, The Institute of Cancer Research and The Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    J Exp Clin Cancer Res 21:107-14. 2002
    ..15 cancers have been detected to date, from a total of 1236 screening measurements. This event rate and the tumour grades reported are compared with recent reports from other studies in women at high risk of breast cancer...
  26. pmc ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer
    T Stankovic
    CRC Institute for Cancer Studies, The Medical School, University of Birmingham, United Kingdom
    Am J Hum Genet 62:334-45. 1998
    ..We also show that 25% of all A-T patients carried in-frame deletions or missense mutations, many of which were also associated with expression of mutant ATM protein...
  27. ncbi request reprint Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene
    P J Biggs
    Section of Molecular Carcinogenesis, Institute of Cancer Research, Haddow Laboratories, Belmont, Sutton, Surrey, UK
    Nat Genet 11:441-3. 1995
    ..Using markers close to the cylindromatosis gene, consistent loss of the wild-type allele was observed in 19 tumours from four individuals in the two families, indicating that the gene is likely to be a tumour suppressor gene...
  28. ncbi request reprint A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability
    C S Healey
    CRC Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
    Nat Genet 26:362-4. 2000
    ..82 in females and 1.38 in males. Therefore, this variant of BRCA2 appears also to affect fetal survival in a sex-dependent manner...
  29. pmc Testicular microlithiasis as a familial risk factor for testicular germ cell tumour
    J Coffey
    Testicular Cancer Genetics Team, Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 97:1701-6. 2007
    ..We suggest that TM is an alternative manifestation of a TGCT susceptibility allele...
  30. ncbi request reprint Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast
    L G Fulford
    The Breakthrough Breast Cancer Research Centre, London, UK
    Histopathology 49:22-34. 2006
    ..Currently, they are not identified in routine practice and no morphological guidelines exist to aid their identification. The aim of this study was to analyse the histological features of CK14+ IDC...
  31. pmc ATM polymorphisms as risk factors for prostate cancer development
    S Angele
    DNA Repair Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69373 Lyon, France
    Br J Cancer 91:783-7. 2004
    ..These results provide evidence that the presence of common variants in the ATM gene, may confer an altered cellular phenotype, and that the ATM 3161C>G variant might be associated with prostate cancer risk...
  32. pmc Role of MC1R variants in uveal melanoma
    N Hearle
    Haddow Laboratories, Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton SM2 5NG, UK
    Br J Cancer 89:1961-5. 2003
    ..We interpret the data as indicating that MC1R variants do not appear to be major determinants of susceptibility to uveal melanoma...
  33. ncbi request reprint Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk
    B Kuschel
    Cancer Research UK Human Cancer Genetics Research Group, Department of Oncology, Strangeways Research Laboratories, Cambridge CB1 8RN, United Kingdom
    Cancer Epidemiol Biomarkers Prev 12:809-12. 2003
    ..It is also unlikely that other, as yet unidentified, common polymorphisms that affect risk are present in the gene in the British population...
  34. ncbi request reprint Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer
    S Bevan
    Molecular and Population Genetics Team, Section of Cancer Genetics, Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    Prostate Cancer Prostatic Dis 6:12-4. 2003
    ..No pathogenic mutations in FH were identified in any of the cases. This data makes it highly unlikely that mutations in FH confer susceptibility to prostate cancer...